Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (MonoferÂ®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from non-hematological malignancies with Chemotherapy induced anaemia.
Non-hematological Malignancies
DRUG: 500 mg iron isomaltoside 1000|DRUG: 1000 mg iron isomaltoside 1000
Total serum iron pharmakokinetic parameters, 24, 48 and 72 hours
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from non-hematological malignancies with Chemotherapy induced anaemia.